Omeros (OMER) Change in Accured Expenses (2010 - 2026)
Omeros' (OMER) quarterly Change in Accured Expenses came in at -$979000.0 in Q1 2026, up 80.58% year-on-year from -$542132.7 in Q1 2025, and up 44.15% quarter-over-quarter from -$1.8 million in Q4 2025.
Omeros (OMER) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Omeros has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$979000.0 for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$979000.0, up 80.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (up 263.61% YoY), and the FY2025 annual result was $4.6 million, up 187.46% from the prior year.
- Change in Accured Expenses came in at -$979000.0 for Q1 2026 at Omeros, up from -$1.8 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.2 million in Q2 2025 to a low of -$15.7 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is $879000.0 (2022), against an average of -$448176.5.
- Across the five-year window, Change in Accured Expenses slumped 781.72% in 2024 and jumped 1336.43% in 2025, its largest moves.
- Omeros' Change in Accured Expenses stood at $879000.0 in 2022, then rose by 7.05% to $941000.0 in 2023, then jumped by 544.63% to $6.1 million in 2024, then sank by 128.9% to -$1.8 million in 2025, then jumped by 44.15% to -$979000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$979000.0 (Q1 2026), -$1.8 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | -979,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -979,000.00 |
| Mar 31, 2026 | -979,000.00 |
| Dec 31, 2025 | -1.75 Mn |
| Dec 31, 2025 | -1.75 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -5.64 Mn |
| Sep 30, 2024 | -5.64 Mn |
| Jun 30, 2024 | -667,000.00 |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -5.00 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | 941,000.00 |
| Dec 31, 2023 | 941,000.00 |